François Boemer1, Michelle Deberg2, Roland Schoos2, Etienne Baise3, Hélène Amory4, Gilbert Gault5, Jeremy Carlier6, Yvan Gaillard6, Christel Marcillaud-Pitel7, Dominique Votion4. 1. Biochemical Genetics Laboratory, Human Genetics, CHU Liege, University of Liege, Belgium. Electronic address: f.boemer@chu.ulg.ac.be. 2. Biochemical Genetics Laboratory, Human Genetics, CHU Liege, University of Liege, Belgium. 3. Department of animal Productions: Biostatistics, Economy and animal selection, Fundamental and Applied Research for Animals & Health (FARAH), Faculty of Veterinary Medicine, University of Liege, Belgium. 4. Equine Pole, Fundamental and Applied Research for Animals & Health (FARAH), Faculty of Veterinary Medicine, University of Liege, Belgium. 5. Usc 1233 Ediss, VETAGROSUP, Ecole nationale vétérinaire de Lyon, France. 6. LAT LUMTOX, La Voulte-sur-Rhône, France. 7. Réseau d'EpidémioSurveillance en Pathologie Equine (RESPE), Caen, France.
Abstract
BACKGROUND: Hypoglycin A has been recently identified has the causal agent of atypical myopathy (AM) in horses. Its identification and quantification in equine's biological fluids is thus a major concern to confirm maple poisoning and to provide insight into the poorly understood mechanism of hypoglycin A intoxication. METHODS: Quantification of hypoglycin A has been achieved with the aTRAQ kit for amino acid analysis of physiological fluids (AB Sciex). Acquisition method on mass spectrometer has been updated to record the hypoglycin A specific MRM transition. RESULTS: Outlined accuracy profiles demonstrated very reliable data. A good linearity was observed from 0.09 to 50μmol/L and precision was very good with coefficient of variation below 8%. Fifty-five samples collected from 25 confirmed AM horses revealed significant hypoglycin A concentrations, while toxin was not found in serum of 8 control animals. CONCLUSIONS: The described aTRAQ variant method has been analytically and clinically validated. The reliability of our approach is thus demonstrated into the workup of atypical myopathy.
BACKGROUND:Hypoglycin A has been recently identified has the causal agent of atypical myopathy (AM) in horses. Its identification and quantification in equine's biological fluids is thus a major concern to confirm maple poisoning and to provide insight into the poorly understood mechanism of hypoglycin A intoxication. METHODS: Quantification of hypoglycin A has been achieved with the aTRAQ kit for amino acid analysis of physiological fluids (AB Sciex). Acquisition method on mass spectrometer has been updated to record the hypoglycin A specific MRM transition. RESULTS: Outlined accuracy profiles demonstrated very reliable data. A good linearity was observed from 0.09 to 50μmol/L and precision was very good with coefficient of variation below 8%. Fifty-five samples collected from 25 confirmed AM horses revealed significant hypoglycin A concentrations, while toxin was not found in serum of 8 control animals. CONCLUSIONS: The described aTRAQ variant method has been analytically and clinically validated. The reliability of our approach is thus demonstrated into the workup of atypical myopathy.
Authors: Aimee A Sanford; Samantha L Isenberg; Melissa D Carter; Mike A Mojica; Thomas P Mathews; Sarah Laughlin; Jerry D Thomas; James L Pirkle; Rudolph C Johnson Journal: J Chromatogr B Analyt Technol Biomed Life Sci Date: 2018-07-20 Impact factor: 3.205